MedTrace Logo

A Long Term Safety Study of Apricitabine in HIV-infected Patients

NCT00686270 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2011-06-23

No results posted yet for this study

Summary

This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria for virological failure/lack of response, and consequently wish to withdraw early from studies AVX-301 or AVX-302.

Conditions

  • HIV Infections

Interventions

DRUG

apricitabine

Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.

Sponsors & Collaborators

  • Avexa

    lead INDUSTRY

Principal Investigators

  • Mike Saag, Professor · UAB Centre for AIDS Research, Birmingham, Alabama, 35294-2050, USA

  • Susan W Cox, PhD · Avexa Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2012-05-31
Completion
2012-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686270 on ClinicalTrials.gov